These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35550204)

  • 21. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.
    Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M
    Am J Psychiatry; 2016 Feb; 173(2):166-73. PubMed ID: 26541815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
    Lin CH; Huang CJ; Lin TC; Chan HY; Chen JJ
    Psychiatry Res; 2023 Dec; 330():115575. PubMed ID: 37913621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.
    Brodeur S; Vanasse A; Courteau J; Stip E; Lesage A; Fleury MJ; Courteau M; Roy MA
    Acta Psychiatr Scand; 2022 May; 145(5):456-468. PubMed ID: 35158404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine.
    Kitagawa K; Uekusa S; Hanai Y; Kimura I; Tsukahara M; Kagawa A; Sasaoka K; Sakishiro Y; Miyake A; Watanabe Y; Baba D; Kodama M; Kishi Y; Yamada N; Yoshio T; Matsuo K
    Asian J Psychiatr; 2024 Jun; 96():104047. PubMed ID: 38640549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
    Taipale H; Tanskanen A; Tiihonen J
    Am J Psychiatry; 2023 May; 180(5):377-385. PubMed ID: 36945825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
    Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
    J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
    Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
    Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.
    Luykx JJ; Stam N; Tanskanen A; Tiihonen J; Taipale H
    Br J Psychiatry; 2020 Sep; 217(3):498-505. PubMed ID: 31910911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 31. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.
    Correll CU; Brevig T; Brain C
    BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey.
    Wang J; Jiang F; Zhang Y; Cotes RO; Yang Y; Liu Z; Ning X; Liu T; Liu Y; Tang YL; Liu H
    Asian J Psychiatr; 2021 Aug; 62():102742. PubMed ID: 34243064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
    Wu YH; Lai CY; Chang YS
    Psychogeriatrics; 2015 Mar; 15(1):7-13. PubMed ID: 25515355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic randomized open-label trial (SwAP trial).
    Shakir M; Willems AE; van Harten PN; van Lutterveld R; Tenback DE
    Schizophr Res; 2022 May; 243():187-194. PubMed ID: 35397249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
    Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
    Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first-episode schizophrenia: A nationwide, health insurance data-based study.
    Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
    Psychiatry Clin Neurosci; 2022 May; 76(5):195-200. PubMed ID: 35233892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to Initiation of Clozapine Treatment in Children and Adolescents with Early-Onset Schizophrenia.
    Trinczek E; Heinzel-Gutenbrunner M; Haberhausen M; Bachmann CJ
    Pharmacopsychiatry; 2016 Nov; 49(6):254-259. PubMed ID: 27737473
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices.
    Grimminck R; Oluboka O; Sihota M; Rutherford DL; Yeung H
    Prim Care Companion CNS Disord; 2020 Jul; 22(4):. PubMed ID: 32678523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
    Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
    Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.